Project Grant R21AG098513
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded the University of Wisconsin–Madison $427,625 on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The recipient is conducting basic research to understand how axon guidance genes contribute to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two neurodegenerative disorders that share a clinical disease spectrum. The research focuses...
- The National Institute on Aging awarded the University of Wisconsin – Madison $424,648 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate ribosome quality control defects in trisomy 21 aging. The project tests a novel hypothesis that premature aging and cellular stress in Down syndrome cells arise from defects in translational fidelity and ribosome quality control caused by chromosome amplification, rather than from specific genes on chromosome 21. The research...
- The National Institute on Aging awarded the University of Wisconsin System $698,690 on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on the molecular mechanisms of fiber type-specific skeletal muscle dysfunction with aging. The research quantifies proteome changes associated with fiber type-specific atrophy in older males and females, determines cross-bridge mechanisms for fiber type-specific impairments in contractile function, and identifies fiber...
- The National Institute on Aging awarded the University of Wisconsin-Madison $427,625 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate cerebral small vessel disease pathways in vascular contributions to cognitive impairment and dementia and Alzheimer's disease using ferumoxytol-enhanced MRI. The research will employ novel microvascular biomarkers including quantitative characterization of vascular density and hemodynamic measures of microvascular pulsatility...
- The National Institute on Aging awarded the University of Pittsburgh $673,702 on September 1, 2026, under the Aging Research program (CFDA 93.866) to support research deciphering ubiquilin-mediated proteostasis mechanisms in Alzheimer's disease and related dementias. The research addresses knowledge gaps in ubiquilin function and protein homeostasis defects underlying neurodegenerative disease. The project will elucidate how STI1 domain binding and E3 ligase recruitment affect cellular fitness...
- The National Institute on Aging awarded the University of Massachusetts Medical School $452,783 on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate molecular mechanisms of neuronal cell death and protection against neurodegeneration. The award funds research into how context-specific molecular mechanisms protect neurons against age-related degeneration, using C. elegans models of excitotoxicity and oxidative stress. The project will determine how TIR-1/SARM1, a...
- The National Institute on Aging, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Wisconsin System Office of Sponsored Programs (operating as University of Wisconsin–Milwaukee) $642,805 under the Aging Research program (CFDA 93.866) on January 15, 2026. The award funds three experiments investigating how older age affects memory integration—the ability to generalize across experiences, make inferences, and accumulate knowledge....
- The National Institute on Aging awarded $427,625 to The Washington University on September 1, 2026, under the Aging Research program (CFDA 93.866) to probe cerebellar cortex computations in Alzheimer's disease. The work examines cerebellar nodulus and uvula function in two Alzheimer's disease mouse models—APP/PS1 and 3XTG-AD—at 3, 6, and 12 months of disease progression to assess how hallmarks of Alzheimer's disease contribute to cerebellar dysfunction. The project tests the hypothesis that...
- The National Institute on Aging awarded Northwestern University $457,112 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of toxic short RNAs (sRNAs) and the DISE (Death Induced by Survival Elimination) mechanism in neurodegenerative diseases, particularly Alzheimer's disease and Huntington's disease. The research examines how G-rich sRNAs target survival genes through miRNA-like pathways and explores why normal tissues remain protected from this cell...
- The National Institute on Aging awarded the University of Alabama at Birmingham $486,779 on September 1, 2026, under the Aging Research program (CFDA 93.866) for research into targeted progranulin therapy as a treatment for TDP-43 proteinopathy, a primary pathology of amyotrophic lateral sclerosis, frontotemporal dementia, and a common co-pathology of Alzheimer's disease. The research investigates whether boosting progranulin levels can provide neuroprotection in TDP-43 proteinopathy by...